MAP2K7 and head and neck squamous cell carcinoma: It is also worth noting that Ngan et al. reported a favorable survival of HNSCC patients with somatic mutations in key components of the MAPK pathway [77], which raises concerns on the clinical benefit of targeted inhibition of the MEK-ERK pathway as a “magic bullet” for all SCC.